Herribert Pavaci
Research Subjects
Research Interests
Herribert Pavaci has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Buiatti
Azienda Sanitaria Universitaria Integrata, University of Trieste (ASUITS)
1 shared publication Arben Perani
Krankenhaus Landshut Achdorf , Achdorfer Weg 3 , Landshut 84036, Germany
1 shared publication- Benito Baldauf
University of Applied Sciences, Bremerhaven, Germany
1 shared publication - Bernhard Zrenner
Krankenhaus Landshut Achdorf , Achdorfer Weg 3 , Landshut 84036, Germany
1 shared publication - Christof Kolb
German Heart Center of Munich , Munich , Germany
1 shared publication Ernest W Lau
Department of Cardiology, Royal Victoria Hospital , Grosvenor Road , Belfast BT12 6BA, UK
1 shared publication
Latest Publications
- Open Access
- 5 October 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (10)
Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection
TauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. The device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802). TauroPace is safe but more effective than H2O2 in reducing CIED infection. ClinicalTrials.gov Identifier: NCT05576194
- 5 October 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (10)
Open AccessUse of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection
TauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. The device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802). TauroPace is safe but more effective than H2O2 in reducing CIED infection. ClinicalTrials.gov Identifier: NCT05576194
- 31 July 2013
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 102 (10) , 781-783
Electromagnetic interference between a three-dimensional cardiac mapping system and an implantable cardioverter defibrillator
- 31 July 2013
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 102 (10) , 781-783
Electromagnetic interference between a three-dimensional cardiac mapping system and an implantable cardioverter defibrillator